Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. M. (René) van Hulst


A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe

A situational and stakeholder analysis of health technology assessment in Zimbabwe

Adherence to protocols for the use of reversal agents in patients treated with direct oral anticoagulants

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Health economic evaluation of nation-wide screening programmes for atrial fibrillation in the Netherlands

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia

Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study

Read more